Copy-number gains in NAALADL2 were found to occur in 15.99% (95% CI:13.02-18.95) of primary prostate cancers with increasing frequency in metastatic, castrate-resistant and neuroendocrine disease. Here, NAALADL2 is linked to prostate cancer.